AVBCC COVID-19 Webcast Series Coverage

Telehealth reimbursement. 340B. Drug pricing negotiations. There’s been a lot of action on healthcare-related proposals in Washington in recent weeks. What’s likely to last, and what is just “political theater”? AVBCC’s panel of experts has the inside scoop.

With many clinical trials on hold and COVID-19 studies the only new trials opening up, how are cancer researchers adapting to the new environment? Can lessons from COVID-19 facilitate improved clinical trial recruitment and retention in the future?

Initiatives to expand patient access programs, strategies to secure the supply chain, and updates on vaccine trials: leaders from top pharmaceutical manufacturers discussed their companies’ ongoing response to the worldwide pandemic in this AVBCC webcast.

With the chaos in the workplace and in healthcare caused by the COVID-19 pandemic, experts predict that most major employers will not be looking to add any more disruption with significant changes to their benefit plans for 2021.

When oncology practices, ranging from small community clinics to larger hospital-based programs, were required to adapt their systems virtually overnight in response to the COVID-19 health crisis, almost no one anticipated that these would be long-term changes. However, as September approaches with no end in sight, it has become clear that oncologists will need to adapt revenue cycle management to long-term pandemic-related changes.

One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects.

From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19.

As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure?

As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials.

Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy.